Drug updated on 10/24/2024
| Dosage Form | Injection (intravenous; 100 mg/20 mL [5 mg/mL]) |
| Drug Class | Folate receptor alpha (FRα)-directed antibodies and microtubule inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with FR positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens
- Select patients for therapy based on an FDA-approved test.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The Objective Response Rate (ORR) for mirvetuximab soravtansine in recurrent ovarian cancer with FRa-positive expression was 36% (95% Confidence Interval (CI): 27%-45%), and as a second-line and above treatment for advanced or recurrent ovarian cancer, it was 34.2% (95% CI: 25.0-43.5%).
- The Progression-Free Survival (PFS) was 6.1 months (95% CI: 4.27-7.47) overall, with 6.26 months (95% CI: 4.67-7.85) specifically for platinum-resistant ovarian cancer, and 5.82 months (95% CI: 4.47-7.18) for another group of patients.
- The Disease Control Rate (DCR) was reported at 88% (95% CI: 84-91%).
- The most common adverse events (AEs) were blurred vision (45%, Grade III: 2%), nausea (42%, Grade III: 1%), and diarrhea (42%, Grade III: 2%). Another source reported an overall AE incidence of 87.4% (95% CI: 52.9-100.0) and grade ≥ 3 AEs incidence of 27.1% (95% CI: 18.9-36.1), with blurred vision (46.7%), nausea (41.8%), and diarrhea (41.3%) being the most frequent AEs.
- There was a high incidence of blurred vision, nausea, and diarrhea, with grade ≥ 3 AEs occurring in 27.1% of patients.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Elahere (mirvetuximab soravtansine-gynx) Prescribing Information. | 2024 | ImmunoGen, Inc., Waltham, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis | 2024 | Critical Reviews in Oncology/Hematology |
| The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis | 2023 | Expert Review of Clinical Pharmacology |